BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...midpoints. Pricing in the middle of their proposed ranges were Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) and Aprea...
BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

...fell through early this month. And among three other biotechs that listed last week, only Aprea...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...$150 million in a bumped up IPO of 7.9 million shares at $19; cancer play Aprea...
BioCentury | Oct 3, 2019
Financial News

After ADC withdraws IPO, three others price offerings

...York Stock Exchange. The three others priced on NASDAQ late Wednesday: Viela Bio Inc. (NASDAQ:VIE), Aprea...
...treat neuromyelitis optica spectrum disorder, is under FDA review (see “MedImmune Spinout Seeks IPO” ). Aprea...
...$298.1 million. It had proposed to sell 5 million shares at $14-$16. During Thursday’s session, Aprea...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...loss. Frequency plans to start a Phase IIa trial next quarter; data are expected 2H20. Aprea Therapeutics AB...
...to sell 5 million shares at $14-$16 in a NASDAQ IPO. At the $15 midpoint, Aprea...
...closed Monday at $14.98. -Associate Editor Stephen Hansen contributed to this report Elizabeth S. Eaton, Staff Writer Aprea Therapeutics AB Frequency...
BioCentury | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

...more than it previously proposed, and be valued at $3.4 billion. Aprea proposes NASDAQ listing Aprea Therapeutics AB...
...products to treat chronic pain. Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor APR-246, prima-1met 10x Genomics Inc. Aprea Therapeutics AB Insilico...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...Janet Dorling as chief commercial officer. She was CCO of Achaogen Inc. (Pink:AKAOQ). Cancer company Aprea Therapeutics AB...
...Alberto Gabizon will also become president of the liposome delivery company. Jonathan Block, Associate Editor Allogene Therapeutics Inc. Aprea Therapeutics AB CymaBay...
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...areas of epigenetics, protein homeostasis and metabolism for cancer, inflammation and neurodegeneration indications. Cancer company Aprea Therapeutics AB...
...partner. Zimmerman, who joined the firm in June 2018, was VP at 6 Dimensions Capital. BioCentury Staff Abingworth Aprea Therapeutics AB Arcus...
BioCentury | Dec 7, 2018
Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

...a Phase III trial this month of APR-246 plus Vidaza to treat p53 mutant MDS. Aprea Therapeutics AB...
...Updated Phase Ib/II data Milestone: Start Phase III (12/2018) Sandi Wong APR-246, prima-1met Vidaza, azacitidine (NS-17) American Society of Hematology Aprea Therapeutics AB ASH H...
BioCentury | Dec 7, 2018
Financial News

Aprea heading for Phase III with €50M series C round

...Formed in 2003 and backed by Karolinska Development AB (SSE:KDEV) for more than a decade, Aprea...
...MDS patients. Schade said the trial has the potential to support the therapy's accelerated approval. Aprea...
...for its next funding, Schade said, although it will consider other options. Aprea Therapeutics AB, Solna, Sweden Paul Bonanos Aprea Therapeutics AB p53...
Items per page:
1 - 10 of 41
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...midpoints. Pricing in the middle of their proposed ranges were Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) and Aprea...
BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

...fell through early this month. And among three other biotechs that listed last week, only Aprea...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...$150 million in a bumped up IPO of 7.9 million shares at $19; cancer play Aprea...
BioCentury | Oct 3, 2019
Financial News

After ADC withdraws IPO, three others price offerings

...York Stock Exchange. The three others priced on NASDAQ late Wednesday: Viela Bio Inc. (NASDAQ:VIE), Aprea...
...treat neuromyelitis optica spectrum disorder, is under FDA review (see “MedImmune Spinout Seeks IPO” ). Aprea...
...$298.1 million. It had proposed to sell 5 million shares at $14-$16. During Thursday’s session, Aprea...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...loss. Frequency plans to start a Phase IIa trial next quarter; data are expected 2H20. Aprea Therapeutics AB...
...to sell 5 million shares at $14-$16 in a NASDAQ IPO. At the $15 midpoint, Aprea...
...closed Monday at $14.98. -Associate Editor Stephen Hansen contributed to this report Elizabeth S. Eaton, Staff Writer Aprea Therapeutics AB Frequency...
BioCentury | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

...more than it previously proposed, and be valued at $3.4 billion. Aprea proposes NASDAQ listing Aprea Therapeutics AB...
...products to treat chronic pain. Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor APR-246, prima-1met 10x Genomics Inc. Aprea Therapeutics AB Insilico...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...Janet Dorling as chief commercial officer. She was CCO of Achaogen Inc. (Pink:AKAOQ). Cancer company Aprea Therapeutics AB...
...Alberto Gabizon will also become president of the liposome delivery company. Jonathan Block, Associate Editor Allogene Therapeutics Inc. Aprea Therapeutics AB CymaBay...
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...areas of epigenetics, protein homeostasis and metabolism for cancer, inflammation and neurodegeneration indications. Cancer company Aprea Therapeutics AB...
...partner. Zimmerman, who joined the firm in June 2018, was VP at 6 Dimensions Capital. BioCentury Staff Abingworth Aprea Therapeutics AB Arcus...
BioCentury | Dec 7, 2018
Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

...a Phase III trial this month of APR-246 plus Vidaza to treat p53 mutant MDS. Aprea Therapeutics AB...
...Updated Phase Ib/II data Milestone: Start Phase III (12/2018) Sandi Wong APR-246, prima-1met Vidaza, azacitidine (NS-17) American Society of Hematology Aprea Therapeutics AB ASH H...
BioCentury | Dec 7, 2018
Financial News

Aprea heading for Phase III with €50M series C round

...Formed in 2003 and backed by Karolinska Development AB (SSE:KDEV) for more than a decade, Aprea...
...MDS patients. Schade said the trial has the potential to support the therapy's accelerated approval. Aprea...
...for its next funding, Schade said, although it will consider other options. Aprea Therapeutics AB, Solna, Sweden Paul Bonanos Aprea Therapeutics AB p53...
Items per page:
1 - 10 of 41